EN DE
Watch Foghorn Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Foghorn Therapeutics Inc (FHTX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Foghorn Therapeutics Inc stock $1.75, price $1.90, that is 7.9% below the price, quality 30 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

FT Foghorn Therapeutics Inc logo Thin data Nov 11, 2026

Foghorn Therapeutics Inc

FHTX · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Revenue last quarter +113% vs. a year ago.
Fair value $1.75 · Fairly valued
Mixed Growth (revenue 5y +135.1 %/yr in USD)
Negative equity (buybacks among others)
Mixed vs. peers (3/7)
Quality 30/100
Loss-making · -175.8% net margin (TTM)
Negative free cash flow
Narrow moat 9/100
Thin data
Estimate
Watch Foghorn Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$22.87 $1.85 Fair Value $1.75 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $1.85 – $22.87 · fair‑value band $1.31 – $2.19 · the $1.90 price screens above the $1.75 fair value. As of Nov 11, 2026.

Follow Foghorn Therapeutics in your weekly email

Every Wednesday you see whether Foghorn Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.

Show moreShow less

The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome.

The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Stock analysis

Foghorn Therapeutics Inc (FHTX) currently trades at $1.90, while our estimate is $1.75, so the stock looks roughly fairly valued today (gap 8.6%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.31 (bear) to $2.19 (bull), the price of $1.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Foghorn Therapeutics Inc reported revenue of $30.9M in FY2025 versus $1.3M in FY2021, a compound +120.0%/yr. Reported net income was −$74.3M in FY2025.

Key figures

Market cap $134M Micro · P/S ratio 3.30 · EPS (TTM) $0.0900 · Return on equity −470% · Return on assets (EBIT) −32.7% (5-year average) · Operating margin −54.8% · Revenue (TTM) $36.7M · Revenue growth (YoY) +113%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 73% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −8%, FHTX screens richer than that median.

Fair Value

Bear $1.31 Fair Value $1.75 Bull $2.19
Price $1.90 · Downside -7.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+36.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+135.1%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15,937.4% (2020) → −265.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch FHTX, get fair value alerts →

Compare Foghorn Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −7.9% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −37.5% · Below median
Net margin (12 months) −175.8% · Bottom 25%
Operating margin (12 months) −54.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 112.7% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 3.65× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)23 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs FHTX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs FHTX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs FHTX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs FHTX
argenx SE ARGX $971.55 $908.40 −7% vs FHTX
CSL Limited CSL A$201.68 A$181.40 −10% vs FHTX
Moderna, Inc MRNA $250.83 $158.70 −37% vs FHTX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs FHTX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs FHTX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs FHTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Foghorn Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Foghorn Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/FHTX

Frequently asked questions

Is Foghorn Therapeutics Inc (FHTX) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $1.75 versus a price of $1.90, about 8% lower (fairly valued).
What is the fair value of FHTX?
Our estimate for Foghorn Therapeutics Inc is $1.75 (as of Nov 11, 2026), built from audited fundamentals. The current price: $1.90.
What is the quality score of FHTX?
Foghorn Therapeutics Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Foghorn Therapeutics Inc (FHTX)?
Our calculated price target is the estimate of $1.75 (as of Nov 11, 2026). Cautious scenario $1.31, optimistic scenario $2.19. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Foghorn Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $1.75, about 8% lower versus a price of $1.90 (fairly valued). Cautious scenario $1.31, optimistic scenario $2.19. The calculation is refreshed regularly with new filings.
What is the revenue of Foghorn Therapeutics Inc (FHTX)?
Foghorn Therapeutics Inc reported trailing-twelve-month revenue of about $36.7M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Foghorn Therapeutics Inc (FHTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Foghorn Therapeutics Inc it is $1.75 per share (as of Nov 11, 2026), against a price of $1.90.
Is Foghorn Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, FHTX trades above its calculated fair value: price $1.90, fair value $1.75, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FHTX?
No. The price is what the market pays today ($1.90); the fair value is what the company's own numbers justify ($1.75). For Foghorn Therapeutics Inc the two are $0.1500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Foghorn Therapeutics Inc worth?
The market values Foghorn Therapeutics Inc at about $134M (market capitalisation, as of Nov 11, 2026). Per share that is $1.90; our models calculate a fair value of $1.75 per share.
What do the bullish and bearish scenarios say about FHTX?
Our models span a range for Foghorn Therapeutics Inc: cautious scenario $1.31, base $1.75, optimistic $2.19 per share (as of Nov 11, 2026, price $1.90). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Foghorn Therapeutics Inc (FHTX)?
Balance-sheet figures for Foghorn Therapeutics Inc (as of Nov 11, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is FHTX from its 52-week high?
Foghorn Therapeutics Inc trades at $1.90, about 73% below its 52-week high of $7.07 and 3% above the low of $1.85 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $1.75 is for.
Which stocks are comparable to Foghorn Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Foghorn Therapeutics Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $1.90, calculated fair value $1.75 (−8%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Foghorn Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Foghorn Therapeutics Inc (FHTX)?
The closing price on Nov 10, 2026 was $1.90. Our estimate is $1.75, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Foghorn Therapeutics Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Foghorn Therapeutics Inc

How large is the market capitalisation of Foghorn Therapeutics Inc (FHTX)?
The market capitalisation of Foghorn Therapeutics Inc is $134M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Foghorn Therapeutics Inc (FHTX)?
The price-to-sales ratio of Foghorn Therapeutics Inc is 3.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Foghorn Therapeutics Inc (FHTX)?
Earnings per share at Foghorn Therapeutics Inc are $0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Foghorn Therapeutics Inc (FHTX)?
The return on equity (ROE) of Foghorn Therapeutics Inc is −470% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Foghorn Therapeutics Inc (FHTX)?
On an EBIT basis the return on assets of Foghorn Therapeutics Inc is −32.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Foghorn Therapeutics Inc (FHTX)?
The operating margin of Foghorn Therapeutics Inc is −54.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Foghorn Therapeutics Inc (FHTX)?
Revenue at Foghorn Therapeutics Inc is growing +113% versus a year earlier (3y avg +17.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Foghorn Therapeutics Inc (FHTX) generate?
The free cash flow of Foghorn Therapeutics Inc is −$86.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Foghorn Therapeutics Inc (FHTX) hold?
Foghorn Therapeutics Inc holds more cash than debt, $39.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Foghorn Therapeutics Inc in the live analysis

One click puts Foghorn Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.